Monistat-Derm Articles
BioAlliance Pharma gets Swiss MA for Loramyc
25 August 2009
BioAlliance turns on SpePharm over JV
9 March 2009
BioAlliance's 3rd-qtr income grows to $1.9M
10 November 2008
BioAlliance extends Loramyc license to China
30 June 2008
Steifel acquires Barrier in $145M deal
30 June 2008
BioAlliance's 1st qtr boosted by Loramyc
2 June 2008
Barrier's 1st-qtr loss narrows 9%
12 May 2008
BioAlliance closer to Loramyc US launch
28 April 2008
BioAlliance licenses Loramyc to Handok
7 April 2008
BioAlliance gains three more EU Loramyc approvals
31 March 2008
BioAlliance's Loramyc cleared in UK and Denmark
14 January 2008
Par's 3rd qtr net falls 70% on Strativa costs
14 January 2008
BioAlliance completes US Phase III Loramyc trial
26 November 2007
BioAlliance's 3rd-qtr income reaches $2.5M
5 November 2007
Miconazole confirms antifungal efficacy at ICAAC
24 September 2007
BioAlliance's first-half net loss increases 76%
17 September 2007
BioAlliance's Loramyc lauched in France
10 September 2007
BioAlliance Pharma in 40M-euro fund raising
6 August 2007
BioAlliance licenses US Loramyc rights to Par
9 July 2007
BioAlliance sets up SpeBio for Loramyc
25 June 2007
BioAlliance forms JV with Spepharm BV
19 March 2007
BioAlliance's 3rd-qtr revenue up 240%
4 December 2006
BioAlliance's Loramyc gets domestic approval
23 October 2006
FDA approves Barrier's Xolegel
7 August 2006
BioAlliance starts Ph III Loramyc trial in USA
22 May 2006
BioAlliance to boost business in US and Europe
22 May 2006
BioAlliance prices IPO
19 December 2005
FDA go-ahead for BioAlliance Miconazole IND
12 September 2005
BioAlliance files IND for Ph III trial of Lauriad
1 August 2005
BioAlliance confirms efficacy of buccal Lauriad
23 May 2005
BioAlliance close to EU filing of Lauriad pill
17 January 2005
Barrier and Healthpoint in Zimycan collaboration
27 September 2004
BioAlliance closes 12 million-euro Series C financing
6 September 2004
Promising new data for Barrier's Zimycan
16 August 2004
Drug development news in brief
10 March 1999
"Disappointing" 1997 For Core Group
2 April 1998
Core Reveals Setback With Moraxen
25 February 1998
Chinese Sales of Joint-Venture Drugs Growing
26 September 1997
Product Swap By J&J And P&U
11 June 1997
Watson Offers $606.5 Million For Circa
10 April 1995
Labelling Change For Cisapride
20 March 1995
Core Technologies Products In Phase II
19 December 1994
Hoechst Products to Be Boycotted In The USA
18 July 1994
Diflucan Indication Extension
18 July 1994
NIZORAL TOPS SKIN DRUG LEAGUE IN 1992
10 January 1994
AL LABS RECEIVES APPROVAL
6 December 1993
EXTENSION TO JAPANESE FORMULARY
11 October 1993
IBUPROFEN OFF DRUGS LIST IN JAPAN
2 August 1993
NEW PRODUCTS ON JAPAN TARIFF LIST
12 April 1993
BROAD SPECTRUM WAY FORWARD IN ANTIFUNGALS
12 April 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
SUCCESSFUL POM-TO-P SWITCHES IN THE UK
9 November 1992
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
BAYER LAUNCHES OTC IMIDAZOLE IN UK
1 June 1992
IMIDAZOLES TO GO OTC IN UK
27 January 1992
Showing 1-64 of 64 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
